生物活性

• 描述Sertindole, a neuroleptic, is one of the antipsychotic medications available. Sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors^[3]. Sertindole is at least as effective as haloperidol and risperidone against the positive symptoms of schizophrenia, while it appears superior against negative symptoms. Sertindole is associated with a low rate of extrapyramidal side effects, lacks sedative properties, and may induce a moderate weight gain^[4]. The incidence of QTc interval prolongation of 500 ms or greater with therapeutic dosages of sertindole has also been low. Unlike other antipsychotic agents, sertindole has not been associated with cognitive impairment, and can actually improve cognitive function^[5]. Long-term treatment with sertindole was safe and well tolerated, and patients showed clinical improvement beyond acute treatment^[6].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02374567	Dementia Depr... more >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Collapse <<	Phase 3	Terminated	-	Germany ... more >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Collapse <<
  NCT02307396	Schizophrenia ... more >> Schizophrenia and Disorders With Psychotic Features Schizoaffective Disorders Collapse <<	Phase 4	Completed	-	Germany ... more >> Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar Munich, Bavaria, Germany, 81675 Collapse <<
  NCT01765829	Psychosis Nos/Other	Phase 3	Unknown	November 2015	Spain ... more >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD    0034956040209    cheman45@gmail.com    Principal Investigator: José María Mongil San Juan, MD          Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD       eva.bravo.barba@gmail.com    Principal Investigator: Eva Bravo Barba, MD          Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD    0034958038849    marial.barrigon.sspa@juntadeandalucia.es    Principal Investigator: María Luisa Barrigón Estévez, MD          Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD    0034953021717    fernandosarramea@hotmail.com    Principal Investigator: Farnando Sarramea Crespo, MD, PhD          Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD       migueortigosa@hotmail.com    Principal Investigator: Miguel Ortigosa Luque, MD          Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD    0034916530108    zamarroluisa@yahoo.es    Principal Investigator: María Luisa Zamarro Arraz, MD, PhD          Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD       rosagutierrez@psiquiatra.e.telefonica.net    Principal Investigator: María Rosario Guitiérrez Labrador, MD          Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD    0034951033931    dgutierrezcastillo@gmail.com    Principal Investigator: Daniel Gutiérrez Castillo, MD          Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD       maribelosunac@hotmail.com    Principal Investigator: María Isabel Osuna Carmona, MD          Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD    0034948266650    nacho.mata70@gmail.com    Principal Investigator: Ignacio Mata Pastor, MD, PhD          Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD    0034955016083    joaquinmartin@hotmail.com    Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD          Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD       maria.lacruz.silvestre@gmail.com    Principal Investigator: María Lacruz Silvestre, MD, PhD          Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd    0034944 006137    sonia.bustamantemadariaga@osakidetza.net    Principal Investigator: Sonia Bustamante Madariaga, MD, PhD          Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD    0034915347363    hergoico@gmail.com    Contact: Ruth Berdún Pe, MD       ruthberdun@yahoo.es    Principal Investigator: Mariano Hernández Monsalve, MD, PhD          Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD       jmolinamar@hotmail.com    Principal Investigator: Juan Dios Molina Martín, MD, PhD          Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD       fermin.mayoral.sspa@juntadeandalucia.es    Principal Investigator: Fermín Mayoral Cleríes, MD, PhD          Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD    0034955013414    claram.rosso.sspa@juntadeandalucia.es    Contact: Miguel Ruiz Veguilla, MD, PhD    0034955013414    mruizveguilla@yahoo.com    Principal Investigator: Miguel Ruiz Veguilla, MD, PhD Collapse <<

• 更多
• 参考文献

• [1] Juruena MF, de Sena EP, et al. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85.

  [2] Murdoch D, Keating GM. Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55.

  [3] Juruena MF, de Sena EP, de Oliveira IR. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85

  [4] Spina E, Zoccali R. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin Drug Metab Toxicol. 2008 May;4(5):629-38

  [5] Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs. 2004;18 Suppl 2:19-30; discussion 41-3

  [6] Hale AS, Azorin JM, Lemming OM, Mæhlum E. Sertindole in the long-term treatment of schizophrenia. Int Clin Psychopharmacol. 2012 Jul;27(4):231-7

• 更多

• Collapse